Literature DB >> 29148140

Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post-capillary pulmonary hypertension.

Stefano Ghio1, Gabriele Crimi1, Pier Luigi Temporelli2, Egidio Traversi3, Maria Teresa La Rovere3, Antonia Cannito1, Dario Vizza4, Laura Scelsi, Claudia Raineri, Marco Guazzi5, Luigi Oltrona Visconti1.   

Abstract

AIMS: The most recent European guidelines have proposed new definitions of pulmonary hypertension (PH) in left heart disease, to better approach the characteristics required to reflect the presence of pulmonary vascular disease. The purpose of this study was to assess whether different haemodynamic definitions of post-capillary PH imply a different reversibility of PH in response to acute vasodilator administration in heart failure patients with reduced ejection fraction and PH (HFrEF-PH). METHODS AND
RESULTS: Right heart catheterization and reversibility testing was performed in 156 HFrEF-PH patients. Patients were classified as combined post-capillary and pre-capillary pulmonary hypertension (Cpc-PH) vs. isolated post-capillary pulmonary hypertension (Ipc-PH) and on the basis of diastolic pulmonary gradient (DPG) ≥ 7 vs. < 7 mmHg or of transpulmonary gradient (TPG) >12 vs. ≤12 mmHg. After vasodilator administration, Cpc-PH patients showed a greater per cent improvement in pulmonary vascular resistance (PVR), DPG and TPG as compared with Ipc-PH patients (all Pint < 0.001); only pulmonary compliance (PCa) improved less in Cpc-PH than in Ipc-PH patients (Pint = 0.007). However, despite vasodilatation, Cpc-PH patients remained in an unfavourable portion of the inverse hyperbolic relationship between PVR and PCa. The number of patients in whom PVR was reduced below 2.5 wood units was similar in Cpc-PH, DPG ≥7 mmHg and TPG >12 mmHg groups (28.3, 26.7 and 18.9%, respectively).
CONCLUSION: Although substantial improvements in PVR, DPG and TPG were observed in Cpc-PH patients after acute vasodilator administration, this response was associated with persistent abnormalities in the PVR vs. PCa relationship. The link between baseline right heart haemodynamics and pulmonary vascular disease remains elusive.
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.

Entities:  

Keywords:  Heart failure; Pulmonary hypertension; Reversibility testing

Mesh:

Substances:

Year:  2017        PMID: 29148140     DOI: 10.1002/ejhf.1067

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  10 in total

1.  Pulmonary Hypertension Subtypes and Mortality in CKD.

Authors:  Daniel L Edmonston; Kishan S Parikh; Sudarshan Rajagopal; Linda K Shaw; Dennis Abraham; Alexander Grabner; Matthew A Sparks; Myles Wolf
Journal:  Am J Kidney Dis       Date:  2019-11-12       Impact factor: 8.860

Review 2.  Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection-Focus on Group II Pulmonary Hypertension.

Authors:  Bhavadharini Ramu; Brian A Houston; Ryan J Tedford
Journal:  Curr Heart Fail Rep       Date:  2018-04

3.  Altered Hemodynamics and End-Organ Damage in Heart Failure: Impact on the Lung and Kidney.

Authors:  Frederik H Verbrugge; Marco Guazzi; Jeffrey M Testani; Barry A Borlaug
Journal:  Circulation       Date:  2020-09-08       Impact factor: 29.690

Review 4.  Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction.

Authors:  Andrea R Levine; Marc A Simon; Mark T Gladwin
Journal:  Trends Cardiovasc Med       Date:  2018-08-17       Impact factor: 6.677

5.  Prognostic Implications of Changes in Left Ventricular Ejection Fraction and Pulmonary Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.

Authors:  Hyun Jin Kim
Journal:  J Cardiovasc Imaging       Date:  2019-10

6.  Prognostic Power of Pulmonary Arterial Compliance Is Boosted by a Hemodynamic Unloading Test With Glyceryl Trinitrate in Heart Failure Patients With Post-capillary Pulmonary Hypertension.

Authors:  Andreas J Rieth; Dimitri Grün; Georgios Zarogiannis; Steffen D Kriechbaum; Sebastian Wolter; Manuel J Richter; Khodr Tello; Ulrich Krüger; Veselin Mitrovic; Stephan Rosenkranz; Christian W Hamm; Till Keller
Journal:  Front Cardiovasc Med       Date:  2022-03-31

7.  Apolipoprotein A1 is associated with pulmonary vascular resistance and adverse clinical outcomes in patients with pulmonary hypertension secondary to heart failure.

Authors:  Wande Yu; Xie Dujiang; Wang Yi; Ding Guanwen; Zhang Mengyu; Pan Chang; Zhang Aikai; Zhang Juan; Zhu Linlin; Zhang Hang
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

8.  Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease.

Authors:  Emmanouil Tampakakis; Sanjiv J Shah; Barry A Borlaug; Peter J Leary; Harnish H Patel; Wayne L Miller; Benjamin W Kelemen; Brian A Houston; Todd M Kolb; Rachel Damico; Stephen C Mathai; Edward K Kasper; Paul M Hassoun; David A Kass; Ryan J Tedford
Journal:  Circ Heart Fail       Date:  2018-04       Impact factor: 8.790

Review 9.  Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues.

Authors:  Emmanuelle Berthelot; Fabrice Bauer; Jean-Christophe Eicher; Erwan Flécher; Barnabas Gellen; Julien Guihaire; Damien Guijarro; Gérald Roul; Muriel Salvat; Christophe Tribouilloy; Florian Zores; Nicolas Lamblin; Pascal de Groote; Thibaud Damy
Journal:  ESC Heart Fail       Date:  2018-07-20

10.  Comparison of levosimendan, NO, and inhaled iloprost for pulmonary hypertension reversibility assessment in heart transplant candidates.

Authors:  Marta Tavares-Silva; Francisca Saraiva; Roberto Pinto; Sandra Amorim; João Carlos Silva; Adelino F Leite-Moreira; Maria Júlia Maciel; André P Lourenço
Journal:  ESC Heart Fail       Date:  2021-02-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.